Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/79415
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Factors underlying regression of coronary atheroma with potent statin therapy
Author: Puri, R.
Nissen, S.
Ballantyne, C.
Barter, P.
Chapman, M.
Erbel, R.
Libby, P.
Raichlen, J.
St. John, J.
Wolski, K.
Uno, K.
Kataoka, Y.
Nicholls, S.
Citation: European Heart Journal, 2013; 34(24):1818-1825
Publisher: W B Saunders Co Ltd
Issue Date: 2013
ISSN: 0195-668X
1522-9645
Statement of
Responsibility: 
Rishi Puri, Steven E. Nissen, Christie M. Ballantyne, Phillip J. Barter, M. John Chapman, Raimund Erbel, Peter Libby, Joel S. Raichlen, Julie St. John, Kathy Wolski, Kiyoko Uno, Yu Kataoka and Stephen J. Nicholls
Abstract: AIMS: Statins can inhibit the progression of coronary atherosclerosis. We aimed to characterize clinical factors that associate with differing measures of coronary atheroma volume following potent statin therapy. METHODS AND RESULTS: SATURN employed serial intravascular ultrasound (IVUS) to monitor changes in measures of coronary atheroma burden [total atheroma volume (TAV) and per cent atheroma volume (PAV)] in 1039 patients with coronary artery disease, treated with rosuvastatin (40 mg) or atorvastatin (80 mg) daily for 24 months. Rosuvastatin-treated patients demonstrated greater reductions in low-density lipoprotein cholesterol (LDL-C, 47 vs. 40%, P < 0.001) and greater increases in high-density lipoprotein cholesterol (HDL-C, 13 vs. 10%, P = 0.02). These alterations in the lipid profile associated with greater TAV (−6.4 vs. −4.4 mm3, P = 0.01), but not PAV (−1.22 vs. −0.99%, P = 0.17) regression. Greater TAV reductions with rosuvastatin vs. atorvastatin occurred in patients with diabetes (P = 0.01, treatment by diabetic status interaction P-value 0.05). Greater PAV reductions with rosuvastatin were evident in females (P = 0.01, treatment by sex interaction P-value 0.03) and in those with greater than or equal to median baseline LDL-C (P = 0.02, treatment by LDL-C group interaction P-value 0.03) or HDL-C levels (P = 0.02, treatment by HDL-C group interaction P-value 0.04). On multivariable analysis assessing change in TAV and PAV, both higher baseline TAV and PAV independently associated with TAV and PAV regression, respectively (standardized estimates: TAV −0.25, P < 0.001; PAV −0.23, P < 0.001). CONCLUSION: Higher-risk patients, particularly those with greater baseline coronary atheroma volume, are more likely to experience less disease progression with potent statin therapy.
Keywords: IVUS; statins; atherosclerosis; risk factors
Rights: Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2013
RMID: 0020130385
DOI: 10.1093/eurheartj/eht084
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.